Suspected immune checkpoint inhibitor‐induced pulmonary sarcoid reaction in metastatic renal cell carcinoma

Abstract

We present the case of a 50-year-old male patient with metastatic clear cell renal cell carcinoma (mRCC) who developed a diffuse pulmonary opacification and lymphadenopathy during nivolumab maintenance therapy. This was diagnosed as presumed sarcoid granulomatous inflammatory reaction secondary to immunotherapy, which resolved with holding off therapy and the nivolumab was resumed. K E Y W O R D Simmune-related adverse events, immunotherapy, metastatic renal cell carcinoma, sarcoid-like reactions How to cite this article: Purcell V, Preti B, Fernandes R. Suspected immune checkpoint inhibitor-induced pulmonary sarcoid reaction in metastatic renal cell carcinoma.

Immune checkpoint inhibitor-associated sarcoidosis reaction

“…In another case report, Purcell et al, described a 50-year-old male with renal cell carcinoma who obtained lymphadenopathy and diffuse pulmonary opacification across nivolumab therapy, which was presumed sarcoid granulomatous inflammatory reaction due to immunotherapy. In their case, the immunotherapy was continued without the development of sarcoidosis or clinical worsening of the patient (13). Moreover, Chanson et al, characterized 32 cases with biopsy-defined sarcoidosis, with a median time of 3 months (range, 2-29 months) between initiation of ICIs therapy and sarcoidosis diagnosis.…”